PMID- 17640777
OWN - NLM
STAT- MEDLINE
DCOM- 20070920
LR  - 20070730
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 25
IP  - 34
DP  - 2007 Aug 21
TI  - Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive 
      patients.
PG  - 6310-2
AB  - This short report presents results of an open uncontrolled single centre study 
      which evaluated immunogenicity and safety of a virosome-formulated hepatitis A 
      vaccine (Epaxal) in 14 HIV-positive adult patients and 64 healthy adults 
      receiving a primary immunisation and a booster dose 12 months later. 
      Seroconversion rates (> or =20 mIU/mL), geometric mean concentration (GMC) of 
      anti-HAV antibodies, local and systemic adverse events (AEs) were assessed at 
      baseline and at Months 1, 6, 12, and 13. The seroconversion rate was 63.6% at 
      Month 1 and 91.7% at Month 13 in HIV-positive patients versus 93.8 and 100% in 
      healthy adults. The booster dose increased GMCs from 25.5 to 659.2 mIU/mL in 
      HIV-positive patients versus 104 and 2986 mIU/mL in healthy adults. Epaxal was 
      well tolerated by the HIV-positive patients and was at least as immunogenic as 
      reported for aluminium-adsorbed vaccines. In conclusion, Epaxal can be considered 
      an immunogenic and safe hepatitis A vaccine in HIV-positive patients.
FAU - Loutan, L
AU  - Loutan L
AD  - Travel and Migration Medicine Unit, Geneva University Hospitals, rue 
      Micheli-du-Crest 24, 1211 Geneva 14, Switzerland.
FAU - Bovier, P
AU  - Bovier P
FAU - Herzog, C
AU  - Herzog C
LA  - eng
PT  - Journal Article
DEP - 20070629
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Hepatitis A Antibodies)
RN  - 0 (Hepatitis A Vaccines)
RN  - 0 (Vaccines, Virosome)
SB  - IM
MH  - Adult
MH  - HIV Seropositivity/*immunology
MH  - Hepatitis A Antibodies/*blood
MH  - Hepatitis A Vaccines/adverse effects/*immunology
MH  - Humans
MH  - Male
MH  - Vaccines, Virosome/adverse effects/*immunology
EDAT- 2007/07/21 09:00
MHDA- 2007/09/21 09:00
CRDT- 2007/07/21 09:00
PHST- 2007/05/04 00:00 [received]
PHST- 2007/06/11 00:00 [revised]
PHST- 2007/06/11 00:00 [accepted]
PHST- 2007/07/21 09:00 [pubmed]
PHST- 2007/09/21 09:00 [medline]
PHST- 2007/07/21 09:00 [entrez]
AID - S0264-410X(07)00691-3 [pii]
AID - 10.1016/j.vaccine.2007.06.013 [doi]
PST - ppublish
SO  - Vaccine. 2007 Aug 21;25(34):6310-2. doi: 10.1016/j.vaccine.2007.06.013. Epub 2007 
      Jun 29.